

VISCHER ADVISED SYNENDOS IN CLOSING CHF 20 MILLION SERIES A FINANCING ROUND

Posted on 20 November 2020



Category: [Deal & transactions](#)

Tags: [Christian Wyss](#), [Dario Glauser](#), [Ex-Featured](#), [Luzius Zumstein](#), [Vischer](#)



Synendos Therapeutics, a biopharmaceutical company developing a new class of small molecules designed to restore the natural function of the endocannabinoid system in the brain and have the potential to treat a variety of central nervous system (CNS) disorders , [closed its Series A financing round of CHF 20 million.](#)

The financing was carried out under the joint management of Kurma Partners and Sunstone Life Science Ventures with the participation of BERNINA BioInvest, Schroder Adveq, High-Tech Gründerfonds, Lichtsteiner Foundation, Essential Investments, Zürcher Kantonalbank and private investors. Synendos will primarily use the funds raised to

The team

VISCHER [advised Synendos on all legal issues in connection with the transaction.](#) The team included **Christian Wyss (Partner, Corporate / M&A - pictured)**, **Luzius Zumstein (Senior Associate, Corporate / M&A)** and **Dario Glauser (Trainee, Corporate / M&A)**.